Etiology/Pathobiology

Anna deFazio, BSc (Hons), PhD

August 18, 2019

Anna deFazio, BSc (Hons), PhDUniversity of Sydney Ovulation-Related Gene Expression Signature Dysregulated in Progression to Cancer Women with a higher number of ovulations throughout their lifetime, without breaks due to pregnancy or oral contraceptives, have increased ovarian cancer risk. Dr. deFazio’s study aims to identify the genes that participate in the ovulation process in normal […]

Read More

Andrew Wilson, PhD

August 18, 2019

Andrew Wilson, PhDVanderbilt University Medical Center The Role of the Nuclear Orphan Receptor TR3/Nur77 in Ovarian Cancer Preliminary results have led to the hypothesis that TR3 is a marker of chemotherapy-induced apoptosis and a potential therapeutic target in ovarian cancer. In this study, three aims will be investigated by Dr. Wilson and his team. First, […]

Read More

Xiaolong He, PhD

August 18, 2019

Xiaolong He, PhDUniversity of Illinois The role of microRNA miR-124 in ovarian cancer Based on his previous work and recent results, Dr. Xiaolong He hypothesizes that microRNA miR-124 may function as a tumor suppressor. In this study, two specific aims are proposed to strengthen the hypothesis. Aim 1 is to examine the levels of miR-124 […]

Read More

William Foulkes, PhD

August 18, 2019

William Foulkes, PhDMcGill University Health Center Novel target discovery in hereditary ovarian cancer by deep sequencing Ovarian cancer is an important cause of death and inherited susceptibility accounts for a substantial fraction of this cancer. Moreover, advances in knowledge of hereditary forms of cancer have led to insights into the more common, non-hereditary forms. Technological […]

Read More

Resham Bhattacharya, PhD

August 18, 2019

Resham Bhattacharya, PhDMayo Clinic Therapeutic targeting of Bmi-1 in ovarian cancer While platinum-based drugs continue to be the foundation of therapy for ovarian cancer, chemoresistance remains the main challenge for effective management of recurrent disease. The development of new therapeutic strategies to combat ovarian cancer is needed. This study will examine the therapeutic potential of […]

Read More

Jian-Jun Wei, MD

August 18, 2019

Jian-Jun Wei, MDNorthwestern University MiR-182 Overexpression in Early Tumorigenesis of High Grade Serous Carcinoma High grade papillary serous carcinoma may arise from serous tubal intraepithelial carcinoma in the fallopian tube. MiR-182 is a small RNA molecule that is significantly overexpressed in both types of carcinomas. Dr. Wei hypothesizes that miR-182 overexpression is a critical and […]

Read More

Christine Walsh, MD

August 18, 2019

Christine Walsh, MDCedars-Sinai Medical Center Genetic Modifiers of BRCA1-Associated Gynecologic Cancer Penetrance Women who inherit a mutation in the BRCA1 gene have a 40% risk of developing ovarian, tubal, or peritoneal cancer. Dr. Walsh is seeking to shed light on genetic and molecular events that lead to tumor development in some women in this high-risk […]

Read More

Alexander Nikitin, MD, PhD

August 18, 2019

Alexander Nikitin, MD, PhDCornell University Role of Stem Cells in Ovarian Cancer Understanding of epithelial ovarian cancer development is critical for designing effective diagnostic and therapeutic approaches. During recent years it has become increasingly clear that cancers may arise from stem and progenitor cells. However, the location of the stem cell compartment of the ovarian […]

Read More

Thuy-Vy Do, PhD

August 18, 2019

Thuy-Vy Do, PhDFox Chase Cancer Center Preclinical Evaluation of Aurora A Kinase and PARP Inhibitor Combination Therapy Women carrying mutations in the breast-cancer associated 1 or 2 (BRCA1/2) genes are at higher risk for developing epithelial ovarian cancer. BRCA1/2 play critical roles in repairing DNA and helping genes avoid mutation. Interestingly, BRCA1/2 is not functioning […]

Read More

Daniela Dinulescu, PhD

August 18, 2019

Daniela Dinulescu, PhDBrigham and Women’s Hospital Experimental Models to Validate a Tubal Cell of Origin for Serous Ovarian Cancer Too little is known about the genetic lesions responsible for ovarian cancer tumor initiation, and uncertainty remains over the specific cell or cells of origin. Data emerging from The Cancer Genome Atlas (TCGA) on the many […]

Read More